← Leaderboards
Mark P De Caestecker
Vanderbilt University
$8,014,159
Attributed
$12,293,198
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,293,198 · 11
By mechanism
R01$7,792,330 · 4
UC2$3,178,608 · 1
R21$834,004 · 2
P30$316,000 · 1
R03$152,256 · 1
R13$20,000 · 2
Top collaborators
- Alan Davidson6 shared
- Neil A Hukriede6 shared
- Donna M Huryn6 shared
- Leo E Otterbein4 shared
- Binghe Wang4 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- David E Ong$4,836,670
- Gautam Bhave$2,693,396
- Claire Edwards$1,226,539
- Marie-Claire Orgebin-Crist$957,367
- Helen B Everts$604,125
Others in their field
Top investigators on “Kidney”
- Jeffrey P Krischer · University Of South Florida$540,222,210
- John M Lachin · George Washington University$155,894,464
- David M Nathan · Massachusetts Institute Of Technology$127,229,266
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$111,521,899
- David Heimbrook · Leidos Biomedical Research, Inc.$83,221,586
- Peter Scott Heeger · Case Western Reserve University$80,562,246
Research focus
KidneyBaseChronic Kidney FailureSeveritiesInjuryMediatingSeriesPlayAcute Renal Failure With Renal Papillary NecrosisInjury To KidneyAffectSignal TransductionMouse ModelResponseCell Culture TechniquesPreventCommunitiesDesignRecoveryIn VivoStructureInnovationPropertyKidney Diseases
Grant awards (37)
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$705,716
R01 · FY2025 · DK
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$678,976
R01 · FY2024 · DK
Therapeutic Optimization of Productive Repair After Acute Kidney Injury$601,717
UC2 · FY2024 · DK
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$707,586
R01 · FY2023 · DK
Therapeutic Optimization of Productive Repair After Acute Kidney Injury$628,302
UC2 · FY2023 · DK
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$750,347
R01 · FY2022 · DK
Therapeutic Optimization of Productive Repair After Acute Kidney Injury$630,202
UC2 · FY2022 · DK
FASEB SRC: The 2nd Acute Kidney Injury Conference: From Bench to Bedside$10,000
R13 · FY2022 · DK · contact PI
Therapeutic Optimization of Productive Repair After Acute Kidney Injury$630,202
UC2 · FY2021 · DK
Vanderbilt Kidney O'brien Center - Enrichment Program$63,200
P30 · FY2021 · DK · contact PI
Therapeutic Optimization of Productive Repair After Acute Kidney Injury$57,983
UC2 · FY2021 · DK
Therapeutic Optimization of Productive Repair After Acute Kidney Injury$630,202
UC2 · FY2020 · DK
Mechanisms and therapeutic manipulation of retinoic acid signaling in Acute Kidney Injury$426,720
R01 · FY2020 · DK · contact PI
Vanderbilt Kidney O'brien Center - Enrichment Program$63,200
P30 · FY2020 · DK · contact PI
Mechanisms and therapeutic manipulation of retinoic acid signaling in Acute Kidney Injury$433,380
R01 · FY2019 · DK · contact PI
Vanderbilt Kidney O'brien Center - Enrichment Program$63,200
P30 · FY2019 · DK · contact PI
FASEB SRC on Acute Kidney Injury: from beside to bench (and back again)$10,000
R13 · FY2019 · DK · contact PI
Mechanisms and therapeutic manipulation of retinoic acid signaling in Acute Kidney Injury$433,830
R01 · FY2018 · DK · contact PI
Vanderbilt Kidney O'brien Center - Enrichment Program$63,200
P30 · FY2018 · DK · contact PI
Mechanisms and therapeutic manipulation of retinoic acid signaling in Acute Kidney Injury$426,720
R01 · FY2017 · DK · contact PI
Vanderbilt Kidney O'brien Center - Enrichment Program$63,200
P30 · FY2017 · DK · contact PI
BMP Signaling and Pulmonary Vasoreactivity$367,567
R01 · FY2013 · HL · contact PI
Mutation Specific Therapies in Patients with HPAH$74,256
R03 · FY2013 · HL · contact PI
BMP Signaling and Pulmonary Vasoreactivity$386,100
R01 · FY2012 · HL · contact PI
Mutation Specific Therapies in Patients with HPAH$78,000
R03 · FY2012 · HL · contact PI
BMP Signaling and Pulmonary Vasoreactivity$390,000
R01 · FY2011 · HL · contact PI
BMP Signaling and Pulmonary Vasoreactivity$390,000
R01 · FY2010 · HL · contact PI
A mouse model of placental insufficiency with abnormal renal medullary patterning$189,638
R21 · FY2010 · HD · contact PI
A mouse model of placental insufficiency with abnormal renal medullary patterning$229,929
R21 · FY2009 · HD · contact PI
Transcriptional Control of Renal Development by CITED1$308,128
R01 · FY2006 · DK · contact PI
Cellular Defects in Familial Pulmonary Hypertension$224,228
R21 · FY2006 · HL · contact PI
Transcriptional Control of Renal Development by CITED1$315,543
R01 · FY2005 · DK
Cellular Defects in Familial Pulmonary Hypertension$190,209
R21 · FY2005 · HL
Transcriptional Control of Renal Development by CITED1$315,543
R01 · FY2004 · DK
Transcriptional Control of Renal Development by CITED1$315,543
R01 · FY2003 · DK
Transcriptional Control of Renal Development by CITED1$105,700
R01 · FY2003 · DK
Transcriptional Control of Renal Development by CITED1$334,931
R01 · FY2002 · DK